NCT01159249 is a Phase 3 clinical trial of Vildagliptin in Type 2 Diabetes, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT01159249?

NCT01159249 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT01159249?

Interventions in NCT01159249: Vildagliptin.

What condition does NCT01159249 study?

NCT01159249 studies Type 2 Diabetes.

Is NCT01159249 still recruiting?

NCT01159249 is currently completed. Last updated 11 December 2020.

Last reviewed 2020-12-11 · How we verify

NCT01159249

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter, Open Label, Long-Term Safety Study of 52 Weeks Treatment With Vildagliptin in Patients With Type 2 Diabetes

Completed Phase 3 Last updated 11 December 2020

What this trial tests

Phase 3 trial testing Vildagliptin in Type 2 Diabetes in 245 participants. Completed in 1 January 2012.

Timeline

1 June 2010

Primary endpoint
1 January 2012

1 January 2012

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	245
Start date	1 June 2010
Primary completion	1 January 2012
Estimated completion	1 January 2012
Sites	24 locations across Japan

Drugs / interventions tested

Vildagliptin (VILDAGLIPTIN) — full drug profile →

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

20 and older, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Measure AEs, vital signs, laboratory evaluations
Time frame: 52 weeks

Sponsor's own description

This study is designed to demonstrate the long-term safety of vildagliptin in patients with type 2 diabetes. This study will study vildagliptin as add-on therapy with metformin, thiazolidinedione, α-glucosidase inhibitor (α-GI), rapid-acting insulin secretagogues in the treatment of type 2 diabetes in Japan.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Vildagliptin

Trials testing the same drug.

NCT05366868 — Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus · Phase 4 · active not recruiting
NCT04300790 — Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients · Phase 2 · completed
NCT05359432 — Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus · Phase 4 · completed
NCT04485845 — Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression · Phase 4 · unknown
NCT04654676 — DPP4 Inhibitor on Glycemic Variability · Phase 4 · completed

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01159249 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 11 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01159249.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing